Progyny, Inc. logo PGNY - Progyny, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 14
HOLD 6
SELL 0
STRONG
SELL
0
| PRICE TARGET: $34.43 DETAILS
HIGH: $40.00
LOW: $28.00
MEDIAN: $35.00
CONSENSUS: $34.43
UPSIDE: 11.93%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Mild
Trading 5.7% above fair value
Current Price $30.76
Bear Case $23.19 24.6% downside ($23.19 - $30.76) / $30.76 = -24.6% 5% stage 1 growth, 11% discount
Fair Value $29.10 5.4% downside ($29.10 - $30.76) / $30.76 = -5.4% 9% stage 1 growth, 11% discount
Bull Case $34.74 12.9% upside ($34.74 - $30.76) / $30.76 = 12.9% 12% stage 1 growth, 11% discount

Adjust Assumptions

9.0%
11.0%
3.0%

Key Value Driver

FCF growth rate (9% base case)

Terminal Value % of EV 38%
Implied Market Multiple 22.9x
Market is pricing in (growth) 10.8% vs our 9.0% base

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $34.43 from 20 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $29.10 per share.

Warnings

Stock-based employee pay equals 225% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions